AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2019
Jul 16, 2019
32254_dirs_2019-07-16_ed797a02-11ec-46f7-9ada-bb046e95347a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2019-07-15
Reporting Person: DICICCO WENDY F (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-07-15 | Stock Option (Right to Buy) | $1.51 | A | 80000.00 | Acquired | 2029-07-15 | Common Stock (80000.00) | Direct |
Footnotes
F1: The option becomes exercisable in three equal annual installments beginning on July 15, 2020.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7